StockDuty ← Dashboard Oct 30, 2026 10:39 AM ET
SignalCorporate

Regeneron Pharmaceuticals Non-GAAP EPS of $20.07 beats by $3.82, revenue of $5.1B beats by $540M

Regeneron EPS beat by $3.82 and revenue beat by $540M.

What happened: Regeneron Pharmaceuticals (REGN) reported Q3 Non-GAAP EPS of $20.07 and revenue of $5.1B, both beating estimates. Key numbers: Non-GAAP EPS $20.07, beat by $3.82. Revenue $5.1B, up 36.0% Y/Y, beat by $540M. The company also provided full year 2026 financial guidance. Why it matters: Both EPS and revenue came in above consensus estimates, and the company issued full year 2026 financial guidance. Coverage: 4 outlets in 24h
Regeneron Pharmaceuticals (REGN) reported Q3 Non-GAAP EPS of $20.07 and revenue of $5.1B, both beating estimates.
Both EPS and revenue came in above consensus estimates, and the company issued full year 2026 financial guidance.
Sources